Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

Articles by Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

Induction Therapy Regimens for Transplant-Eligible NDMM

ByJoshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Alfred L. Garfall, MD, Abramson Cancer Center,Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

June 27th 2023

Key opinion leaders on multiple myeloma management review available induction therapy regimens in the transplant-eligible setting.

NDMM: Identifying Patient and Disease Factors to Select Appropriate Therapy

ByJoshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Alfred L. Garfall, MD, Abramson Cancer Center,Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

June 20th 2023

Comprehensive insight on patient and disease characteristics that help to inform best available therapy for patients with newly diagnosed multiple myeloma.

What is the Role of Transplant in Newly Diagnosed Multiple Myeloma?

ByJoshua Richter, MD, Tisch Cancer Center at Mount Sinai,Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Alfred L. Garfall, MD, Abramson Cancer Center,Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

June 20th 2023

Expert panelists reflect on the continuing role of stem cell transplant in patients with newly diagnosed multiple myeloma.

Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

Articles by Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute

Induction Therapy Regimens for Transplant-Eligible NDMM

NDMM: Identifying Patient and Disease Factors to Select Appropriate Therapy

What is the Role of Transplant in Newly Diagnosed Multiple Myeloma?

Trending on OncLive

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies

Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis

FDA Approves Larger Vial Size for Nelarabine Injection in T-ALL and T-LBL